ERBB2 and breast cancer: However, the result obtained from another phase III trial on Nelipepimut-S Vaccine (a cancer vaccine comprised of HLA A2/A3 restricted HER2/neu) indicated acceptable tolerance but no significant clinical benefit in preventing BC recurrence (Mittendorf et al., 2019).